# Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

> **NCT05460195** · PHASE2 · UNKNOWN · sponsor: **Shanghai Chest Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- Minimal Residual Disease
- Immunotherapy
- Anti-angiogenesis

## Interventions

- **DRUG:** sintilimab combined with anlotinib
- **DRUG:** sintilimab monotherapy

## Key facts

- **NCT ID:** NCT05460195
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2022-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05460195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05460195, "Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05460195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*